Evaluation of single dose protection afforded by the prophylactic HPV vaccines
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- HHSN261201700012I
- Awardee
-
Fundacion Inciensa UEI KDL2VERNRKA5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 8 $94,187,550 obligated
Award facts
- Opportunity
-
- N01CP7101582 Solicitation number
- Evaluation of Single Dose Protection Afforded by the Prophylactic HPV Vaccines Award Notice · Posted Dec 23, 2016
- Combined order value
-
- $94,187,550 Current, with exercised options
- $95,734,395 Potential, with all options
- Last date to order 100% complete
- IDV ceiling 94% used
- $100,000,000.00
- Maximum order
- $100,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Sealed Bid
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a single-award indefinite-delivery contract to Fundacion Inciensa on August 1, 2017, with a ceiling of $100 million for evaluation of single-dose protection afforded by prophylactic HPV vaccines. The contract was originally structured with an ultimate completion date of July 31, 2023, and carries no set-aside designation.
Work is performed in Costa Rica. The IDIQ supports conducting human papillomavirus vaccine clinical trials, enrolling and immunizing study participants, following up with enrolled cohorts, collecting and analyzing epidemiological and clinical data, and performing laboratory testing of biospecimens to evaluate vaccine efficacy.
The contract has generated substantial ordering activity. Recent delivery orders include a $6.98 million firm fixed-price order issued February 1, 2023, for PRISMA and EXTEND 2.0 Follow-up of Study Participants, with completion scheduled for January 31, 2027. A $2.93 million order awarded September 26, 2022, supports laboratory testing of biospecimens collected from HPV vaccine study participants, with ultimate completion September 25, 2027; a March 2025 modification de-scoped Option 3 of this order pursuant to the Department of Government Efficiency cost efficiency initiative. Earlier orders under the IDIQ included a $55.31 million delivery order for follow-up and extended follow-up of participants awarded April 6, 2018, completing September 15, 2026, and a $22.97 million order for one-dose trial setup, enrollment, and immunization awarded August 1, 2017, originally completing July 31, 2020. Additional orders supported the PRIMAVERA-ESCUDDO clinical trial and COVID-19 transmission research in Costa Rica.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HHSN261201700012I?
HHSN261201700012I was awarded to Fundacion Inciensa by National Cancer Institute (National Institutes of Health) on August 1, 2017.
How much is contract HHSN261201700012I worth?
Orders under HHSN261201700012I have obligated $94,187,550. Their combined potential value, with all options, is $95,734,395. HHSN261201700012I's own ceiling is $100,000,000. A single order can be worth up to $100,000,000.
How many orders have been placed under contract HHSN261201700012I?
8 orders have been placed under HHSN261201700012I, the latest on February 1, 2023.
Who can order from contract HHSN261201700012I?
HHSN261201700012I is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract HHSN261201700012I competed?
The extent of competition for HHSN261201700012I was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV